vaccines

IRP’s John T. Schiller Elected to National Academy of Sciences

NIH Scientist’s Decoy Virus Revolutionizes Cervical Cancer Prevention

Dr. John T. Schiller

The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.

IRP senior investigator John T. Schiller, Ph.D., was elected to the NAS in 2020 in recognition of a career that has produced numerous discoveries about human papillomaviruses (HPV), sexually transmitted infections that cause genital warts and are responsible for most cases of cervical cancer. His decades-long partnership with fellow IRP senior investigator Douglas R. Lowy, M.D., who was elected to the NAS in 2009, has yielded a deeper understanding of how HPV infects and damages cells and led to the creation of the first vaccines to prevent HPV infection.

An Ebola Therapy Two Decades in the Making

IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment

a volunteer receives an infusion of an experimental Ebola therapy during a phase I clinical trial

Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.

Pandemic Brings All Hands on Deck

IRP Investigators Begin Hundreds of New Coronavirus-Related Studies

coronavirus particles (gold) emerging from an infected cell

Within just a few months after COVID-19 began spreading in the United States, IRP researchers had already made numerous important contributions to the fight against the deadly virus. Scientific knowledge about the disease continues to expand at a unprecedented pace, and the IRP will continue to play a major role in this effort over the coming months and years. In fact, nearly 300 new intramural research projects related to the novel coronavirus are currently starting up or have already begun.

A Long Tradition of Vaccine Breakthroughs

IRP Vaccine Research Stretches Back to the NIH’s Birth

Dr. Meyer (left) and Dr. Parkman (right), along with fellow NIAID scientist Hope Hopps, inspect a culture of the virus that causes rubella

Over the past few months, the world has gained a new appreciation for the long, difficult process of producing vaccines as it waits anxiously for one that will provide protection from the novel coronavirus. With the NIH Vaccine Research Center’s efforts to develop a COVID19 vaccine drawing a huge amount of media attention, it is easy to forget that the IRP has been making vital contributions to vaccine development for more than 100 years. These efforts have helped produce vaccinations for smallpox, rubella, hepatitis A, whooping cough, human papillomavirus (HPV), and several other diseases. Read on for a visual journey through the history of IRP vaccine research. 

IRP’s Anthony Fauci Talks COVID-19 With Stephen Curry

Infectious Disease Expert Interviewed by NBA Superstar

As the COVID-19 illness has continued to spread, so has anxiety, fear, and uncertainty. Now more than ever, we need communicators who can provide clear explanations about the latest research and public health guidelines.

IRP senior investigator Anthony Fauci, Ph.D., has been one of the most prominent voices providing information about the novel coronavirus over the past several weeks. Dr. Fauci, who serves as director of the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), seems to be doing everything he can to make sure the American public has the best information available about the current situation, from speaking at White House press briefings to appearing on television shows like The Daily Show with Trevor Noah. Last Thursday, March 26, Dr. Fauci participated in a live Q&A with NBA superstar Stephen Curry on Curry’s Instagram page. Read on for a few highlights from their discussion, or click on the video below to watch the entire conversation.

Teaching an Old Vaccine New Tricks to Thwart Tuberculosis

The IRP’s Mario Roederer and Robert Seder Discuss the Science Behind the Headlines

Mycobacterium tuberculosis bacteria, the cause of tuberculosis

Some say that if something’s not broken, then don’t fix it, but that doesn’t mean there’s no room for improvement. At least, those were the thoughts of IRP senior investigators Mario Roederer, Ph.D., and Robert Alan Seder, M.D., who recently found that the century-old tuberculosis (TB) vaccine is far more effective when administered via injection into a vein (IV) rather than into the skin, which has long been the standard way it is given. This major breakthrough received extensive media coverage, including a story in the New York Times. We went Behind the Headlines to get the inside scoop on this potentially life-saving discovery.

A New Approach to Fighting the Flu

Six Questions With Dr. Matthew Memoli

person receiving a flu shot

We all know flu season as the time of year where people are loading up on hand sanitizer and heading to the doctor for their flu shot. However, many underestimate the severity of the flu. During a typical flu season, five to twenty percent of Americans fall ill, leading to more than 200,000 hospitalizations and 36,000 deaths. Because of this serious threat to the public, the IRP has a long track record of researching vaccines, antivirals, diagnostics, and other resources in an effort to prevent individuals from catching the flu and improve care for those who do.

NIH History Heats Up

Summer has finally arrived, and it's once again time to shine some light on NIH's rich history. Over the past couple months, NIH has celebrated several important anniversaries, including the 20th birthday of NIH's Vaccine Research Center and the 70th anniversary of the NIH Record newsletter. Read on to learn more about these milestones and other fun facts and intriguing objects from NIH's past!

women exercising in the NIH Fitness Center

HIV Research Yields an Unexpected Discovery

A Conversation with Dr. Paolo Lusso

Dr. Paolo Lusso

First discovered in 1981, human immunodeficiency virus, or HIV, caused one of the most deadly and persistent epidemics in history. HIV destroys CD4+ T cells, a type of white blood cell essential for fighting infection. In doing so, HIV destroys the body’s ability to fight off disease, which often leads to life-threatening consequences. 

Today, medications have allowed people living with HIV to lead healthier lives. However, HIV still remains a major public health concern and continues to be studied by researchers within the IRP and beyond.

IRP research has produced findings essential to the development of current HIV treatments and tools for diagnosis. However, there is still a lot left to learn. One recent IRP contribution to HIV research was a 2017 study led by IRP senior investigator Paolo Lusso, M.D., Ph.D., which suggests that treatments targeting a protein called integrin α4β7 could potentially become an addition to current treatment options for those with HIV, or provide new measures to prevent infection.

What's New In the NIH Archives

The waning weeks of 2018 were busy ones in the Office of NIH History. We're constantly receiving and cataloguing new donations of historic equipment, images, publications, and more. It’s time to see what our donors have given us lately!


"I thought why could you not invert the concept? Instead of laying down hundreds or thousands of probes, how about laying down hundreds or thousands of tissue spots and probing them one antibody or gene probe at a time," remembers Dr. Juha Kononen of the National Human Genome Research Institute (NHGRI) about his idea that led to this prototype manual microarray. Tissue array technology performs rapid molecular profiling of hundreds of normal and pathological tissue specimens or cultured cells. Dr. Kononen worked with Drs. Olli Kallioniemi and Stephen B. Leighton to design this tissue microarray which was initially used in the Cancer Genomics Branch. Now, the National Cancer Institute's Tissue Array Research Program (TARP) develops and distributes multi-tumor tissue microarray slides to cancer researchers based on this technology. The quote comes from a 2002 article published in The Scientist.

tissue microarray